- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/725 - T-cell receptors
Patent holdings for IPC class C07K 14/725
Total number of patents in this class: 8564
10-year publication summary
|
316
|
427
|
606
|
690
|
863
|
1046
|
894
|
798
|
740
|
151
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1133 |
554 |
| The Trustees of the University of Pennsylvania | 4405 |
251 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2962 |
224 |
| The Regents of the University of California | 20473 |
147 |
| Memorial Sloan-Kettering Cancer Center | 2010 |
147 |
| Autolus Limited | 264 |
127 |
| Board of Regents, The University of Texas System | 6036 |
119 |
| Novartis AG | 10467 |
114 |
| Juno Therapeutics, Inc. | 486 |
107 |
| Regeneron Pharmaceuticals, Inc. | 4571 |
104 |
| Immunocore Limited | 230 |
90 |
| Cellectis | 409 |
89 |
| City of Hope | 1016 |
86 |
| CRISPR Therapeutics AG | 377 |
84 |
| Kite Pharma, Inc. | 429 |
83 |
| Lentigen Technology, Inc. | 105 |
79 |
| Fred Hutchinson Cancer Center | 464 |
74 |
| Adaptimmune Limited | 165 |
68 |
| The Board of Trustees of the Leland Stanford Junior University | 6605 |
66 |
| Medigene Immunotherapies GmbH | 77 |
54 |
| Other owners | 5897 |